Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project

Jan Taprogge*, Alex Vergara-Gil, Francesca Leek, Carla Abreu, Lenka Vávrová, Lily Carnegie-Peake, Sarah Schumann, Uta Eberlein, Michael Lassmann, Tino Schurrat, Markus Luster, Frederik A. Verburg, Delphine Vallot, Lavinia Vija, Frédéric Courbon, Kate Newbold, Manuel Bardiès, Glenn Flux

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
22 Downloads (Pure)

Abstract

Purpose: Dosimetry is rarely performed for the treatment of differentiated thyroid cancer patients with Na[131I]I (radioiodine), and information regarding absorbed doses delivered is limited. Collection of dosimetry data in a multi-centre setting requires standardised quantitative imaging and dosimetry. A multi-national, multi-centre clinical study was performed to assess absorbed doses delivered to normal organs for differentiated thyroid cancer patients treated with Na[131I]I. Methods: Patients were enrolled in four centres and administered fixed activities of 1.1 or 3.7 GBq of Na[131I]I using rhTSH stimulation or under thyroid hormone withdrawal according to local protocols. Patients were imaged using SPECT(/CT) at variable imaging time-points following standardised acquisition and reconstruction protocols. Whole-body retention data were collected. Dosimetry for normal organs was performed at two dosimetry centres and results collated. Results: One hundred and five patients were recruited. Median absorbed doses per unit administered activity of 0.44, 0.14, 0.05 and 0.16 mGy/MBq were determined for the salivary glands of patients treated at centre 1, 2, 3 and 4, respectively. Median whole-body absorbed doses for 1.1 and 3.7 GBq were 0.05 Gy and 0.16 Gy, respectively. Median whole-body absorbed doses per unit administered activity of 0.04, 0.05, 0.04 and 0.04 mGy/MBq were calculated for centre 1, 2, 3 and 4, respectively. Conclusions: A wide range of normal organ doses were observed for differentiated thyroid cancer patients treated with Na[131I]I, highlighting the necessity for individualised dosimetry. The results show that data may be collated from multiple centres if minimum standards for the acquisition and dosimetry protocols can be achieved.

Original languageEnglish
Pages (from-to)3225-3234
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume50
Issue number11
DOIs
Publication statusPublished - Sept 2023

Bibliographical note

Funding Information:
The MEDIRAD project has received funding from the Euratom research and training programme 2014–2018 under grant agreement no. 755523. The RTTQA group is funded by the National Institute for Health Research (NIHR). This study represents independent research funded by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.

Funding Information:
We would like to thank the teams at the Royal Marsden Hospital, Universitätsklinikum Marburg, Universitätsklinikum Würzburg and Institute Universitaire du Cancer de Toulouse Oncopole for their support in performing the site set-up measurements and data collection for the MEDIRAD study.

Publisher Copyright:
© 2023, The Author(s).

Fingerprint

Dive into the research topics of 'Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project'. Together they form a unique fingerprint.

Cite this